AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16844713
Drug: Intravenous levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levodopa infusion
Trial: 10752492
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg at bedtime
Trial: 9203718
Drug: Oral poliovirus
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral poliovirus vaccine (OPV) during NID
Trial: 8381091
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo prednisolone treatment
Trial: 3079540
Drug: 4.5 X
RxNorm normalized name: Hydrocodone Bitartrate and Acetaminophen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4.5 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Trial: 3079540
Drug: 90 X
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Trial: 26300329
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy (CBT and NCT combined)
Trial: 18498589
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of dental implants
Trial: 18498589
Drug: Moderately rough
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately rough surface implants
Trial: 18498589
Drug: Novel one-piece
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel one-piece implant design
Trial: 12549992
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (not specified dosage or duration)
Trial: 12549992
Drug: Raloxifene (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (specific dosage and duration not mentioned)
Trial: 8816210
Drug: Dexamethasone therapy
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone therapy (0.5 mg/kg per day for 5 days)
Trial: 8112809
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg zinc/p.o./day as 200 mg 'zinc sulphate tablets
Trial: 8112809
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no zinc administration)
Trial: 25346818
Drug: Caudal injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal injection
Trial: 25346818
Drug: Transforaminal injection
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal injection
Trial: 21692827
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg kg⁻¹ infusions at weeks 0, 2, 6, 12 and 18
Trial: 21692827
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg kg⁻¹ infusions
Trial: 20601389
Drug: Higher in-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher in-treatment HR in time-varying multivariable Cox models
Trial: 1815112
Drug: Interpleural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural block (IPB) with 10 ml 0.5% plain bupivacaine (n = 15)
Trial: 1815112
Drug: Spinal analgesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal analgesia with 15 mg 0.5% heavy bupivacaine and meperidine 1 mg/kg IV and diazepam 10 mg total dose (n = 10)
Trial: 25376160
Drug: Prolonged-release trazodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release trazodone (150-450 mg)
Trial: 22289412
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula supplemented with complex milk lipid (11 to 12 μg/ml gangliosides)
Trial: 19889508
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (weekly educational newsletters)
Trial: 18303079
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (CEEs) 0.625 mg/d for 12 weeks
Trial: 18303079
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2) 0.05 mg/d for 12 weeks
Trial: 16002420
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin/tazobactam (13.5 g over 24 h)
Trial: 16002420
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of piperacillin/tazobactam (3.375 g every 6 h)
Trial: 16002420
Drug: Both infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both infusion methods (intermittent and continuous)
Trial: 8770708
Drug: Intensive plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive plasma exchange (IPE) or whole blood exchange (WBE) in addition to standard medical therapy
Trial: 2061418
Drug: Preventive program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive program based on plaque control and topical application of fluoride, with scaling, root planning, and conventional caries therapy; preventive measures recalled every 2-3 months for 6 years, then 1-2 times per year for 9 years, with a subgroup recalled 3-6 times per year.
Trial: 6349652
Drug: Meclofenamate sodium
RxNorm normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium (300 mg per day for 4 weeks)
Trial: 28403154
Drug: 56mg/day magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56mg/day magnesium cream
Trial: 21136163
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive medications
Trial: 21136163
Drug: No antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antihypertensive medications
Trial: 19070525
Drug: Nitazoxanide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (15 mg/kg/day, twice a day for three days)
Trial: 19070525
Drug: Probiotics (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (1 g, twice a day for five days)
Trial: 19070525
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (control)
Trial: 11385811
Drug: Established inhalational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established inhalational devices (pressurized metered dose inhalers)
Trial: 7978134
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg.kg-1
Trial: 25693013
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of propranolol per kilogram per day for 6 months
Trial: 25693013
Drug: Propranolol (successful
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (successful treatment)
Trial: 22118955
Drug: Quercetin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 150 mg/d for 8 weeks
Trial: 19758254
Drug: Photodynamic antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic antimicrobial therapy (PACT) with 47 J cm(‐2) of irradiation
Trial: 19758254
Drug: Photodynamic antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic antimicrobial therapy (PACT) with 94 J cm(‐2) of irradiation
Trial: 11435905
Drug: Lofepramine and
RxNorm normalized name: lofepramine
DrugBank: Lofepramine (DB13411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofepramine and L-phenylalanine
Trial: 7844206
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone agonist (GnRH-a) in a long-term protocol with human menopausal gonadotrophin (HMG)
Trial: 7844206
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone agonist (GnRH-a) in a short protocol with human menopausal gonadotrophin (HMG)
Trial: 3132484
Drug: 2000‐mg calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000‐mg calcium diet for 8 weeks
Trial: 3132484
Drug: 300‐mg calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300‐mg calcium diet for 1, 2, 4, and 8 weeks
Trial: 27644469
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab injections
Trial: 22388304
Drug: Nitroglycerin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin plus diltiazem (200 μg nitroglycerin plus 2.5 mg diltiazem)
Trial: 22388304
Drug: Nitroglycerin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin alone (200 μg nitroglycerin plus placebo)
Trial: 15665739
Drug: Sirolimus maintenance
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus maintenance therapy after cyclosporine withdrawal
Trial: 7861018
Drug: Stavudine at
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine at 0.1 mg/kg/day
Trial: 7861018
Drug: Stavudine at
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine at 0.5 mg/kg/day
Trial: 7861018
Drug: Stavudine at
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stavudine at 2.0 mg/kg/day
Trial: 1953510
Drug: Flexible dose
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dose induction protocol
Trial: 1953510
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment by resident medical staff
Trial: 7372069
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate therapy
Trial: 22336250
Drug: Propionyl-L-carnitine (PLC)
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (PLC) 6g/day
Trial: 21771118
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (n=342)
Trial: 21771118
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=346)
Trial: 19947445
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy (various classes including diuretics, calcium antagonists, ACE inhibitors, and angiotensin II receptor antagonists)
Trial: 17172556
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (motor imagery and physical practice)
Trial: 17172556
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy alone (control group)
Trial: 7696942
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (Sandoglobulin, Sandoz Pharmaceuticals) at a dose of 700 mg/kg for infants weighing 501-1000 g and 900 mg/kg for those weighing 1001-1500 g, repeated every 14 days until 1800 g or discharge/death
Trial: 7696942
Drug: Placebo infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions during phase I (n = 623), no infusion during phase II (n = 589)
Trial: 2577441
Drug: Chlordesmethyldiazepam 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordesmethyldiazepam 0.1 mg/kg‐1 i.v. (group C)
Trial: 2577441
Drug: Sodium thiopental
RxNorm normalized name: Thiopental Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium thiopental 5 mg/kg‐1 i.v. (Group T)
Trial: 389815
Drug: Co-trimazine (410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimazine (410 mg sulphadiazine plus 90 mg trimethoprim)
Trial: 389815
Drug: Co-trimoxazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim)
Trial: 25151583
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment with premolar extraction (n = 30)
Trial: 25151583
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment without premolar extraction (n = 34)
Trial: 25151583
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, no orthodontic treatment (n = 65)
Trial: 19617465
Drug: Golimumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (50 mg or 100 mg every 4 weeks)
Trial: 17877100
Drug: Hormone status,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone status, gynecologic surgery, alcohol intake, age, educational attainment
Trial: 3289931
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diltiazem plus digoxin
Trial: 28267480
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg betrixaban
Trial: 28267480
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg betrixaban
Trial: 21736887
Drug: Acetazolamide (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (7 mg/kg)
Trial: 21736887
Drug: Saline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline treatment (control)
Trial: 18426998
Drug: N(G)‐monomethyl‐l‐arginine (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)‐monomethyl‐l‐arginine (lower dose)
Trial: 18426998
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 mg PO)
Trial: 18426998
Drug: N(G)‐monomethyl‐l‐arginine (infusion)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)‐monomethyl‐l‐arginine (infusion)
Trial: 18426998
Drug: Phenylephrine (equipressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (equipressor doses)
Trial: 16568340
Drug: Vibration muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration muscle exercise (RVE, 2x6 min daily)
Trial: 8565026
Drug: HCQ 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ 800 mg/d
Trial: 2201541
Drug: Slow-release carbamazepine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release carbamazepine (SR) preparation
Trial: 2201541
Drug: Conventional carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional carbamazepine (C) preparation
Trial: 7302260
Drug: 100 mcg
RxNorm normalized name: Levo-T 100 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg 15(R)-15-methyl prostaglandin E2 (PG)
Trial: 28865815
Drug: Anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory drugs only (Group A)
Trial: 28865815
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for 3 days + anti-inflammatory drugs (Group B)
Trial: 28865815
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of antibiotic 1 hour before extraction + anti-inflammatory drugs (Group C)
Trial: 28865815
Drug: Mouthwash for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash for 7 days + anti-inflammatory drugs (Group D)
Trial: 25919834
Drug: Impaired insight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired insight into delusions (assessed after 3 weeks of treatment)
Trial: 25919834
Drug: Impaired insight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired insight into delusions (assessed after 6 weeks of treatment)
Trial: 25919834
Drug: Impaired insight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired insight into delusions (assessed after 8 weeks of treatment)
Trial: 19609738
Drug: CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP levels ≥7 mg/L
Trial: 19609738
Drug: CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP levels <7 mg/L
Trial: 7920977
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (lipid-supplemented solution)
Trial: 7920977
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (predominantly carbohydrate solution)
Trial: 30947825
Drug: Landmark-based injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landmark-based injection
Trial: 28961996
Drug: Amoxicillin-containing regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-containing regimens
Trial: 28961996
Drug: Clarithromycin triple
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin triple therapy
Trial: 28961996
Drug: Breakpoint of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakpoint of amoxicillin resistance ≥0.125 mg/L
Trial: 20501520
Drug: Remifentanil (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.3 μg/kg/min)
Trial: 22935482
Drug: ACEI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI therapy
Trial: 17144553
Drug: Muscular contrapulsation
RxNorm normalized name: Orchis mascula whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscular contrapulsation (MCP) in combination with balneotherapy (radon and iodine-bromine baths)
Trial: 14658990
Drug: Systematic approach
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic approach to treatment including patient education, encouragement of exposure, attention to relevant comorbidities, use of empirically proven pharmacotherapies, and psychosocial interventions of adequate intensity and duration.
Trial: 8736458
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment for 1 month
Trial: 1550474
Drug: Liquid oral
RxNorm normalized name: M-End Liquid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral intake 4 hours after removal of the tube
Trial: 3875296
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg bwxh nimodipine
Trial: 3875296
Drug: 0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg bwxh nimodipine
Trial: 28058753
Drug: gemigliptin 50
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin 50 mg
Trial: 31502749
Drug: gemigliptin 50
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin 50 mg and dapagliflozin 10 mg
Trial: 22491353
Drug: Oral alpha‐methyl‐para‐tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alpha‐methyl‐para‐tyrosine (AMPT)
Trial: 20410913
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 or 3 g day(‐1) plus oral corticosteroids
Trial: 20410913
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oral corticosteroids
Trial: 15823285
Drug: orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orlistat 120 mg plus a moderate-fat meal (MFO)
Trial: 15823285
Drug: orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orlistat 120 mg plus a high-fat meal (HFO)
Trial: 12433452
Drug: Salbutamol dry
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol dry powder formulations (50 microg to 400 microg)
Trial: 10526025
Drug: Single-stage laparoscopic
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stage laparoscopic management (Group B): Single-stage laparoscopic treatment.